Spleen cells from young but not old immunized mice eradicate large established cancers

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2526-2533

  Schreiber, Karin ^a   Arina, Ainhoa ^a   Engels, Boris ^a   Spiotto, Michael T ^a   Sidney, John ^b   Sette, Alessandro ^b   Karrison, Theodore G ^a   Weichselbaum, Ralph R ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P68; RNA HELICASE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL THERAPY; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; ENZYME MODIFICATION; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; SOLID TUMOR; SPLEEN CELL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84860524550     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0127     Document Type: Article

References (50)

1. Stricker TP, Kumar V. Neoplasia. In: Kumar V, Abbas AK, Fausto N, Aster J, editors. Robbins & Cotran pathologic basis of disease. 8 ed. Philadelphia: WB Saunders; 2009.
2. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012;1:172-8.
3. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-8. (Pubitemid 38667621)
4. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, TigheMP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 2010;184:4215-27.
5. Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011;20:755-67.
6. Peters RL, Rabstein LS, Spahn GJ, Madison RM, Huebner RJ. Incidence of spontaneous neoplasms in breeding and retired breeder BALB-cCr mice throughout the natural life span. Int J Cancer 1972;10:273-82.
7. Bode G, Hartig F, Hebold G, Czerwek H. Incidence of spontaneous tumors in laboratory rats. Exp Pathol 1985;28:235-43. (Pubitemid 16222097)
8. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 1996;24: 710-6. (Pubitemid 27029916)
9. Harding C, Pompei F, Wilson R. Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer 2012;118:1371-86.
10. Spellman CW, Daynes RA. Immunoregulation by ultraviolet light-III. Enhancement of suppressor cell activity in older animals. Exp Gerontol 1978;13:141-6. (Pubitemid 8400889)
11. Flood PM, Urban JL, Kripke ML, Schreiber H. Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med 1981;154:275-90. (Pubitemid 11044162)
12. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004;173:4510-5. (Pubitemid 39280681)
13. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4. (Pubitemid 35231542)
14. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73. (Pubitemid 35462767)
15. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703. (Pubitemid 351860862)
16. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
17. Kochenderfer JN, Dudley ME, Feldman SA,Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti- CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20.
18. Mullen CA, Urban JL, Van Waes C, Rowley DA, Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med 1985;162:1665-82. (Pubitemid 16195366)
19. Schreiber K, Wu TH, Kast WM, Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res 2001;7:871s-5s. (Pubitemid 33600939)
20. Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JC, et al. The immunodominant antigen of an ultravioletinduced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 1997;185:695-705. (Pubitemid 27098154)
21. Fujita T, Nolan GP, Ghosh S, Baltimore D. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev 1992;6:775-87.
22. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43. (Pubitemid 23111402)
23. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, et al. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 2007;178:7890-901. (Pubitemid 46898061)
24. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM. Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol 2001;Chapter 18:Unit 18 3.
25. Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, Grey H, et al. Correlates of protection efficacy induced by vaccinia virusspecific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009;39:717-22.
26. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B. Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 2011;31:137-46.
27. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8. (Pubitemid 44571976)
28. Steentoft C, Schjoldager KT, Clo E, Mandel U, Levery SB, Pedersen JW, et al. Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). Glycoconj J 2010;27:571-82.
29. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990;87:4207-11.
30. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995;2:45-59.
31. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995;92:7976-80.
32. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
33. Spiotto MT, Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 2005;5:8.
34. Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008;68:1563-71. (Pubitemid 351346866)
35. Miller RA. The aging immune system: primer and prospectus. Science 1996;273:70-4. (Pubitemid 26255423)
36. Zhang X, Fujii H, Kishimoto H, LeRoy E, Surh CD, Sprent J. Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells. J Exp Med 2002;195:283-93. (Pubitemid 34461486)
37. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91. (Pubitemid 24121987)
38. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008;49 Suppl 1:27-34.
39. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010;116:5045-9.
40. Ryu SJ, Jung KM, Yoo HS, Kim TW, Kim S, Chang J, et al. CognateCD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60. Blood 2009;113:4273-80.
41. Bos R, Sherman LA. CD4+T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010;70:8368-77.
42. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010;207:2469-77.
43. Garcia GG, Miller RA. Single-cell analyses reveal two defects in peptide-specific activation of naive T cells from aged mice. J Immunol 2001;166:3151-7. (Pubitemid 33117312)
44. Willimsky G, Blankenstein T. Sporadic immunogenic tumors avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-6. (Pubitemid 41613441)
45. Engels B, Rowley DA, Schreiber H. Targeting stroma to treat cancers. Semin Cancer Biol 2012;22:41-9.
46. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155: 1151-64.
47. Afzali B, Mitchell PJ, Scotta C, Canavan J, Edozie FC, Fazekasova H, et al. Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. Am J Transplant 2011;11:1734-42.
48. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92. (Pubitemid 41361997)
49. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008;181:3291-300.
50. Woglom WH. Immunity to transplantable tumors. Cancer Rev 1929;4: 129-214.